LuyePharma

• HOME
• ABOUT LUYEPHARMA
  • Company Overview
  • Corporate Value
  • Board and Management
  • Social Responsibility
• GROUP COMPANIES
• PRODUCTS
  • Oncology Products
    • CMNa®
      (Sodium Glycididazole Injection)
    • LIPUSU®
      (Paclitaxel Liposome Injection)
    • TIANDIXIN®
      (Lentinan Injection)
    • TIANDIDA®
      (Amifostine Injection)
  • Orthepaedics Products
    • MAITONGNA® (Sodium Aescinate Injection)
    • SIDINUO®
      (Elcatonin injection)
    • OKAI®
      (Sodium Aescinate tablet)
    • OLAI®
      (Compound Sodium Aescinate Gel)
    • OTONG®
      (Capsaicin Gel)
  • Cardiovascular Products
    • XUEZHIKANG®
      (Red Yeast Rice Capsules)
  • Hepatology Products
    • LUTINGNUO®
      (Reduced Glutathione Injection)
  • Neurlolgy Products
    • JINSIPING®
      (Selegiline Hydrochloride Tablet)
  • Gynecology Products
    • XIMINGTING®
      (Largetrifoliolious Bugbane Rhizome Tablet)
  • Gastroenterlology Product
    • NUOSEN®
      (Sodium Pantoprazole Injection)
    • SAILIMAI®
      (Smectite Dispersible Tablet)
    • PANTOPRAZOLE PELLETS CAPSULE
    • Smectite Powder Sachet
• R&D AND PIPELINE
• ACTIVITIES AND EVENTS
• INVESTOR RELATIONS
  • Investor Relations Home
  • Financial Statements
  • Financial Highlights
  • Financials Ratios
  • Financial Calendar
  • Stock Information
  • Stock Fundamentals
  • Investment Calculator
  • Newsroom
  • Streaming Video
  • Presentation Slides
  • Email Alerts
• CAREER
• CONTACT US

News

Luye Pharma Achieves 59.1% Growth In 1QFY09 Pre-Tax Profit To RMB 35.4 Million

Please see attached.

Attachments

1. Attachment 1 (Size: 56,562 bytes)